132 related articles for article (PubMed ID: 21359415)
21. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
Schefler AC; Koca E; Bernicker EH; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
[TBL] [Abstract][Full Text] [Related]
22. Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.
Hemminger JA; Toland AE; Scharschmidt TJ; Mayerson JL; Guttridge DC; Iwenofu OH
Mod Pathol; 2014 Sep; 27(9):1238-45. PubMed ID: 24457462
[TBL] [Abstract][Full Text] [Related]
23. Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries.
Behrends U; Schneider I; Rössler S; Frauenknecht H; Golbeck A; Lechner B; Eigenstetter G; Zobywalski C; Müller-Weihrich S; Graubner U; Schmid I; Sackerer D; Späth M; Goetz C; Prantl F; Asmuss HP; Bise K; Mautner J
Int J Cancer; 2003 Aug; 106(2):244-51. PubMed ID: 12800201
[TBL] [Abstract][Full Text] [Related]
24. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.
Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M
Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516
[TBL] [Abstract][Full Text] [Related]
25. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
26. DNA content and other prognostic features in childhood medulloblastoma. Proposal of a scoring system.
Schofield DE; Yunis EJ; Geyer JR; Albright AL; Berger MS; Taylor SR
Cancer; 1992 Mar; 69(5):1307-14. PubMed ID: 1739930
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of folate receptor 1 in medulloblastoma and the correlation with clinicopathological characters and target therapeutic potential.
Liu H; Sun Q; Zhang M; Zhang Z; Fan X; Yuan H; Li C; Guo Y; Ning W; Sun Y; Song Y; Yu C
Oncotarget; 2017 Apr; 8(14):23048-23060. PubMed ID: 28416738
[TBL] [Abstract][Full Text] [Related]
28. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
[TBL] [Abstract][Full Text] [Related]
29. MiR-495 is a Predictive Biomarker that Downregulates GFI1 Expression in Medulloblastoma.
Wang C; Yun Z; Zhao T; Liu X; Ma X
Cell Physiol Biochem; 2015; 36(4):1430-9. PubMed ID: 26160036
[TBL] [Abstract][Full Text] [Related]
30. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
[TBL] [Abstract][Full Text] [Related]
31. Medulloblastoma: from molecular pathology to therapy.
Rossi A; Caracciolo V; Russo G; Reiss K; Giordano A
Clin Cancer Res; 2008 Feb; 14(4):971-6. PubMed ID: 18281528
[TBL] [Abstract][Full Text] [Related]
32. PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis.
Pezuk JA; Brassesco MS; de Oliveira RS; Machado HR; Neder L; Scrideli CA; Tone LG
Childs Nerv Syst; 2017 Apr; 33(4):609-615. PubMed ID: 28283778
[TBL] [Abstract][Full Text] [Related]
33. Emerging treatments and gene expression profiling in high-risk medulloblastoma.
Sardi I; Cavalieri D; Massimino M
Paediatr Drugs; 2007; 9(2):81-96. PubMed ID: 17407364
[TBL] [Abstract][Full Text] [Related]
34. A molecular fingerprint for medulloblastoma.
Lee Y; Miller HL; Jensen P; Hernan R; Connelly M; Wetmore C; Zindy F; Roussel MF; Curran T; Gilbertson RJ; McKinnon PJ
Cancer Res; 2003 Sep; 63(17):5428-37. PubMed ID: 14500378
[TBL] [Abstract][Full Text] [Related]
35. Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.
Lerut E; Van Poppel H; Joniau S; Gruselle O; Coche T; Therasse P
Int J Clin Exp Pathol; 2015; 8(8):9522-32. PubMed ID: 26464715
[TBL] [Abstract][Full Text] [Related]
36. PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia.
Steinbach D; Pfaffendorf N; Wittig S; Gruhn B
Cancer Genet Cytogenet; 2007 Aug; 177(1):51-4. PubMed ID: 17693191
[TBL] [Abstract][Full Text] [Related]
37. High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy.
Frühwald MC; O'Dorisio MS; Pietsch T; Reubi JC
Pediatr Res; 1999 May; 45(5 Pt 1):697-708. PubMed ID: 10231868
[TBL] [Abstract][Full Text] [Related]
38. Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile.
Sadighi Z; Vats T; Khatua S
J Child Neurol; 2012 Oct; 27(10):1302-7. PubMed ID: 22826514
[TBL] [Abstract][Full Text] [Related]
39. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
Thompson MC; Fuller C; Hogg TL; Dalton J; Finkelstein D; Lau CC; Chintagumpala M; Adesina A; Ashley DM; Kellie SJ; Taylor MD; Curran T; Gajjar A; Gilbertson RJ
J Clin Oncol; 2006 Apr; 24(12):1924-31. PubMed ID: 16567768
[TBL] [Abstract][Full Text] [Related]
40. What neurodegeneration, brain malformation and cancer might have in common? An abnormal gene expression!
Kok F
Arq Neuropsiquiatr; 2011 Feb; 69(1):1-2. PubMed ID: 21359413
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
